Skip to main content
Premium Trial:

Request an Annual Quote

Cellix Raises $1.4M in Second-Round Funding to Develop Cell-Based Screening Platform

NEW YORK (GenomeWeb News) – Cellix, a Dublin, Ireland-based developer of cell-based screening tools, said today that it has raised €1.1 million ($1.4 million) in second-round investment.
 
The company previously raised €800,000 in December 2006.
 
Cellix said that the new financing, provided by NCB Ventures of Ireland and OTC Asset Management of France, will enable it to accelerate development and commercialization of its Venaflux screening platform to address a range of therapeutic areas, including atherosclerosis, diabetes, oncology, and autoimmune disorders. 
 
VenaFlux measures cell adhesion to antibody-coated or endothelial-cell cultured microchannels in order to mimic human blood flow. The company said that it is seeing “significant growth” for the platform, which is currently in use at AstraZeneca, Pfizer, Sanofi-Aventis, and Servier.
 
Cellix will use the financing to support continued R&D “as well as further expansion into international markets.”

The Scan

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.